• Skip to primary navigation
  • Skip to main content

National Forum

  • Home
  • About
    • Advisory Leadership Council
    • Board of Directors
    • 2021-22 Strategic Plan
    • History
    • National Forum Awards
    • Team
    • Support
  • Collaborations
    • Counter Cholesterol™
    • Flu Prevention
    • Know Your Numbers
    • Million Hearts®
      • Million Hearts® Stakeholders Flu Vaccination Campaign ’22
    • Move with the Mayor™
    • Signature Reports
    • Stronger Hearts™
    • Value & Access
      • Value & Innovation Forum
  • Events
    • National Forum and Member Events
    • Health Equity Benefits Everyone – January 2023
    • 2022 Annual Meeting
    • 2022 Mid-Year Virtual Convening
    • 2021 Annual Meeting
    • 2021 Mid-Year Virtual Convening
    • Heart Failure Roundtable
    • Value & Innovation Forum
    • Meeting Archives
      • 2020 Annual Meeting
      • 2020 Mid-Year Meeting
      • 2019 Annual Meeting
      • 2019 Virtual Convening on Stroke
      • 2019 Mid-Year Member Meeting
      • 2018 Annual Meeting
      • 2018 Mid Year Meeting
  • Members
    • Membership
  • Newsroom
  • Search Toggle
  • Skip to content

Magnitude of ASCVD Warrants Higher Priority Than Assigned by Advisory Committee: Important for Patient Access to Therapies

Posted on 03.02.21

 

 

For Immediate Release
March 2, 2021
Contact: John M. Clymer
Executive Director
202-903-7303

 

Magnitude of ASCVD Warrants Higher Priority Than Assigned by Advisory Committee
Important for Patient Access to Therapies

While ICER’s advisory committee judged secondary prevention of atherosclerotic cardiovascular disease (ASCVD) to be of average or low priority, the magnitude of the condition says otherwise. Cardiovascular disease (CVD) is the leading cause of death in the U.S. and high cholesterol is a major risk factor for CVD. Nearly 3 in 10 American adults have high LDL or bad cholesterol which leads to ASCVD and raises their risk of heart attack and stroke. Many people struggle to get their cholesterol under control because they need stronger therapies and/or they are unable to take statins. New therapies such as bempedoic acid and inclisiran will provide patients and their clinicians with additional treatment options.

The National Forum for Heart Disease & Stroke Prevention’s Value & Access Steering Committee, comprised of diverse stakeholders, pointed out to ICER and its advisory committee that ICER’s model assumed ezetimibe use at a much higher level than occurs in the real world. Cost-effectiveness based on modeling assumptions that do not hold up in the real world could open the door for formulary decisions that would have the effect of reducing treatment options for patients.

Related:
National Forum ED Addresses ICER Advisory Committee on High Cholesterol Treatments
Value & Access Steering Committee & Partners Comment on ICER Draft Evidence Report on High Cholesterol Treatment

Categories: In the News, News Releases, Value & Access

1150 Connecticut Ave., NW, Suite 300, Washington, DC 20036 Phone: (866) 894-3500
Copyright © 2023 National Forum for Heart Disease & Stroke Prevention. All Rights Reserved
  • Facebook
  • Twitter
  • YouTube
Contact

"*" indicates required fields

Name * Required
This field is for validation purposes and should be left unchanged.